RT @ericdeinmd: #EULAR2022 POS0282 Febuxostat vs allopurinol: CV risk population study âï¸16% reduction in all-cause
Tweet Content
#EULAR2022 POS0282
Febuxostat vs allopurinol: CV risk population study
⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction
⭐️CV safety non-inferior to allopurinol
@Rheumnow https://t.co/1oDSioQWPT
Show on Archive Page
On
Display in Search Results
On
PDQ
Off